Oncotarget

Reviews:

Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases

Jingfei Guo _, Qian Zhang, Xinyu Bi, Jianguo Zhou, Zhiyu Li, Zhen Huang, Yefan Zhang, Muxing Li, Xiao Chen, Xuhui Hu, Chi Yihebali, Junbo Liang, Jianmei Liu, Jianjun Zhao, Jianqiang Cai and Hong Zhao

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:17396-17405. https://doi.org/10.18632/oncotarget.14156

Metrics: PDF 2429 views  |   HTML 2777 views  |   ?  


Abstract

Jingfei Guo1,2,*, Qian Zhang3,*, Xinyu Bi1, Jianguo Zhou1, Zhiyu Li1, Zhen Huang1, Yefan Zhang1, Muxing Li1, Xiao Chen1, Xuhui Hu1, Chi Yihebali4, Junbo Liang5, Jianmei Liu6, Jianjun Zhao1, Jianqiang Cai1, Hong Zhao1

1Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China

2Academy of Medical Sciences, Peking Union Medical College, Beijing, China

3Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

4Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China

5State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

6Laboratory of Cell and Molecular Biology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Hong Zhao, email: [email protected]

Jianqiang Cai, email: [email protected]

Jianjun Zhao, email: [email protected]

Keywords: midgut neuroendocrine tumor, liver metastasis, palliative surgery, primary tumor resection, survival benefit

Received: August 15, 2016     Accepted: November 07, 2016     Published: December 24, 2016

ABSTRACT

Background: Treatment for midgut neuroendocrine tumor patients with unresectable liver metastasis has long been a controversial issue. This system review aims to summarize existing evidence concerning the value of primary tumor resection in this group of patients.

Results: 8 cohort studies were identified for qualitative analysis. None of them strictly met with the inclusion criteria and meta-analysis was impossible. There was a tendency towards better overall survival for the primary tumor resected group in all 8 studies, in which 6 demonstrated significant difference. Progression free survival to liver disease was prolonged and less patients died of liver failure in the resected group.

Methods: MEDLINE, EMBASE and CENTRAL were searched until 2016/7/4 for relevant studies, with primary outcome being overall survival, and secondary outcome being progression free survival, cause of death and symptom relief.

Conclusions: Current evidence supports resection of primary tumor for midgut neuroendocrine tumor patients with liver metastases, but randomized controlled trials are required to reach a final conclusion.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14156